Prescriber's Corner
Teclistamab-cqyv: The First Bispecific T-Cell Engager Antibody for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
Gwen Hua,(1) PharmD, BCOP, Ryan Scanlan,(2) PharmD Candidate, Rachael Straining,(1) PharmD, BCOP, and Daniel S. Carlson,(3) DO
From (1)Geisinger Enterprise Pharmacy, Danville, Pennsylvania; (2)Temple University, Philadelphia, Pennsylvania; (3)Department of Hematology and Medical Oncology, Danville, Pennsylvania
Authors’ disclosures of conflicts of interest are found at the end of this article.
Correspondence to: Gwen Hua, PharmD, BCOP, Geisinger Enterprise Pharmacy, 100 N Academy Ave, Danville, PA 17822
E-mail: ghua@geisinger.edu
J Adv Pract Oncol 2023;14(2):163–171 |
https://doi.org/10.6004/jadpro.2023.14.2.7 |
© 2023 Harborside™
ABSTRACT
Multiple myeloma (MM) remains an incurable malignancy originating from plasma cells. Despite significant advances in treatment, relapses remain inevitable, and novel therapies continue to be needed. Teclistamab-cqyv is a first-in-class, bispecific T-cell engager (BiTE) antibody for the treatment of MM. Teclistamab-cqyv activates the immune system by binding to the cluster of differentiation 3 (CD3) receptor expressed on the surface of T cells and to the B-cell maturation antigen (BCMA) expressed on the surface of MM cells and some healthy B-lineage cells. Teclistamab-cqyv has been shown to be effective in a pivotal trial that demonstrated an overall response rate of more than 60% in heavily pretreated patients. Compared with other BCMA-targeted agents, the side effect profile of teclistamab-cqyv suggests a more tolerable option for elderly patients. Teclistamab-cqyv is now approved by the US Food and Drug Administration (FDA) as monotherapy for the treatment of adult patients with relapsed or refractory MM.
For access to the full length article, please
sign in.
